Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Find out when rewards points are truly worth it. Maximize your benefits and learn how to save more on your travels.
15,541 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A durable capex cycle is forming around upgrading the power grid to handle AI, EV charging, and reshoring needs. Anal...
KelpDAO publicly disputes LayerZero's account of the April breach and unveils plans to migrate to Chainlink CCIP, sig...
A five week surge in spot Bitcoin ETF inflows signals renewed institutional interest as hedging flows fade. This arti...
This in-depth look breaks down Unity's Q1 2026 earnings call, outlining revenue drivers, profitability, and what the ...
A ransomware attack on Canvas disrupted finals across thousands of schools as the ShinyHunters group claimed responsi...
A new wave of gains in the best casino stocks tracks improving consumer sentiment and growth in online gaming. The se...
In May, a calmer approach can shine. This article highlights two dividend stocks that are no-brainer buys for conserv...
The AI race keeps evolving, and Alphabet sits at the center. A rumored Anthropic cloud deal hints at how hyperscale i...
Malibu Boats shows resilience in wake-boat demand and margin discipline in Q3 2026. This guide breaks down the number...
Wells Fargo analysts warn the AI investment surge resembles a euphoric bubble, advising investors to ride gains while...
This guide breaks down the dynatrace (dt) 2026 earnings narrative for investors. It covers growth drivers, margins, g...